media – Page 36 – Pharma & Medical Industry Insights Hub | Drugdu Insights & Updates

HPV Vaccine Protecting Against Infections, Even Among Unvaccinated

Depending on which vaccine they received, HPV infections fell by 76% to 98% over 17 years among vaccinated women, researchers reported in the journal JAMA Pediatrics. But infections also fell by 72% to 76% among unvaccinated women during the same period, results showed. “There are two encouraging takeaways from our study,” said senior researcher Dr. Jessica Kahn, chair of head and neck pathology at the Albert Einstein College of Medicine in New York City. “First, HPV vaccines work remarkably well in a real-world setting, even among women at high risk for HPV and who may not have received all vaccine doses,” she said in a news release. “Second, we saw clear evidence of herd immunity, meaning when enough people are vaccinated, the vaccine indirectly protects unvaccinated people by reducing overall virus transmission.” Kahn said these results “reinforce the potential of the HPV vaccine to prevent infection and, ultimately, eliminate cervical cancer globally.” Long-lasting ...
- Source: drugdu
- 103
- October 2, 2025
The company’s Phase III clinical study of the nine-valent HPV vaccine is ongoing.

an investor asked on the investor interaction platform: When is the company’s nine-valent vaccine expected to be launched? What is its current stage? What is the annual production capacity of the company’s production line? Watson Bio(300142.SZ) stated on the investor interaction platform on September 24 that the company’s related work on the Phase III clinical study of the nine-valent HPV vaccine is ongoing. If there is any substantial and phased progress in the research and development of the company’s vaccine, the company will disclose it in a timely manner. Please pay attention to the relevant information disclosed by the company for subsequent progress. Source；https://finance.eastmoney.com/a/202509243522306220.html
- Source: drugdu
- 176
- October 2, 2025
The company has acquired a controlling stake in Chenan Bio by increasing capital this year.

SecuritiesDaily News Zhifei BiologyWhen answering investors’ questions on the interactive platform on September 26, it was stated that the company had achieved controlling stake in Chenan Bio through capital increase this year, and the company’s business had extended from vaccines to metabolic diseases. Source：https://finance.eastmoney.com/a/202509263524977168.html
- Source: drugdu
- 112
- October 2, 2025
CKBA Cream, a subsidiary of the holding company, has been approved for clinical trials for rosacea.

Taienkang announced that its controlling subsidiary, Broad Venture Park, has received a “Notice of Approval for Drug Clinical Trial” from the National Medical Products Administration (NMPA), authorizing the conduct of a Phase II/III seamless adaptive clinical trial of CKBA Cream for the rosacea indication. CKBA Cream is a topical preparation independently developed by Broad Venture Park and is a Category 1 innovative chemical drug. To date, no Category 1 innovative drug for the treatment of rosacea has been approved for marketing in China . Tainkang’s innovative drug has been approved for clinical trials and is expected to fill the treatment gap for rosacea indications in China . If clinical trials can prove its efficacy, the market potential is considerable. Source：https://www.stcn.com/article/detail/3358450.html
- Source: drugdu
- 95
- October 2, 2025
Another indication for ADC bispecific antibody Iza-Bren has been included in the Breakthrough Therapy List

Baili Tianheng issued an announcement stating that the company’s independently developed iza-bren (EGFR×HER3 dual-antibody ADC), the world’s first, new concept and the only one to enter the Phase III clinical stage, is used for patients with unresectable locally advanced or metastatic urothelial carcinoma who have failed previous treatment with platinum-containing chemotherapy and PD-1/PD-L1 inhibitors. It has been included in the list of breakthrough therapies by the Drug Review Center of the National Medical Products Administration. To date, seven indications of Iza-bren have been included in the list of breakthrough therapies by the Center for Drug Evaluation, and one indication has been granted breakthrough therapy designation by the U.S. Food and Drug Administration. The National Medical Products Administration’s Center for Drug Evaluation prioritizes resources for drugs included in the Breakthrough Therapy designation, strengthening guidance and promoting drug development. Baili Tianheng’s Iza-bren has been designated a Breakthrough Therapy, which is expected to ...
- Source: drugdu
- 134
- October 2, 2025
Luoxin Pharmaceutical plans to raise no more than 842 million yuan for innovative drug research and development! Losing 2.8 billion yuan in three years, causing a sharp drop in monetary funds

On the evening of September 29th, Luoxin Pharmaceutical (002793) announced that it plans to raise no more than 842 million yuan for innovative drug research and development projects, raw material drug expansion and freeze-drying workshop technology renovation projects, and to supplement working capital. According to the data, Luoxin Pharmaceutical is mainly engaged in the research, development, production and sales of pharmaceutical products, focusing on digestion, respiration, anti-tumor and other advantageous fields. Its products are mainly chemical preparations, chemical raw materials, and traditional Chinese patent medicines and simple preparations. The company was listed on the Shenzhen Stock Exchange in April 2016. Luoxin Pharmaceutical stated that in order to strengthen the company’s innovative drug product layout and improve the market competitiveness of innovative drug products, the innovative drug research and development project in this fundraising investment project will focus on the Phase II and III clinical studies of LX22001 for injection to ...
- Source: drugdu
- 137
- October 2, 2025
Changchun High tech goes public in Hong Kong, ‘Hormone Grass’ accelerates search for breakthrough path

Changchun High tech, which once dominated the capital market with growth hormone, is accelerating its plan to go public in Hong Kong after experiencing a performance slump, attempting to find a new way out in the midst of difficulties. On September 29th, according to the Hong Kong Stock Exchange, Changchun High Tech Industry (Group) Co., Ltd. (referred to as “Changchun High Tech”) from Changchun, Jilin submitted a prospectus to the Hong Kong Stock Exchange, intending to be listed on the main board of Hong Kong. Changchun High Tech was listed on the Shenzhen Stock Exchange on December 18, 1996, and as of the close of trading on September 29, 2025, its total market value was RMB 52.583 billion. This marks the official launch of the “A+H” dual platform listing journey for the growth hormone Mao, which once created a “myth” in the A-share market. A pharmaceutical industry analyst from a ...
- Source: drugdu
- 349
- October 2, 2025
DUPHAT

Organiser: INDEX Conferences & Exhibitions Time：March 24 – March 26, 2026 address：Sheikh Zayed Road, Trade Centre 2 Area, Dubai, United Arab Emirates Exhibition hall：Exhibition Hall: Dubai World Trade Centre Product range: Finished Pharmaceuticals: Various over-the-counter and prescription drugs, different types of traditional Chinese medicines, Western medicines, new drugs, special-effect drugs, biopharmaceuticals, Chinese herbal medicines, raw herbal materials, various bulk pharmaceuticals, chemical pharmaceuticals, pharmaceutical intermediates, medical products, etc. Bulk Pharmaceuticals (Intermediates): Vitamins, hormones, sulfonamides, antipyretic analgesics, tetracyclines, amino acids and their derivatives, chloramphenicols, digestive system drugs, other anti-infective agents, penicillins, aminoglycosides, lincomycins, cardiovascular drugs, antiparasitic drugs, cephalosporins, macrolides, respiratory drugs, central nervous system drugs, and other Western medicine raw materials. Excipients and Dosage Forms: Excipients, glidants, enteric-coating materials, antioxidants, sweeteners, penetration enhancers, preservatives, disintegrants, coating materials, surfactants, opacifiers, flavors, filter aids, stabilizers, lubricants, plasticizers, solvents, flavor correctors, colorants, clarifying agents, pH regulators, and others. Pharmaceutical Technology: Production equipment and technologies for ...
- Source: drugdu
- 109
- October 2, 2025
【EXPERT Q&A】What is the process for CE certification?

Drugdu.com expert’s response: CE certification is a mandatory safety certification for products entering the EU market. Its process aims to ensure that products comply with the basic requirements of the EU’s New Approach to Technical Harmonization and Standardization directives, covering aspects such as safety, health, environmental protection, and consumer protection. Below is a detailed overview of the CE certification process and key points: I. Core Process Steps Determine Applicable Directives and Standards Directive Identification: Based on the product type (e.g., electrical equipment, machinery, medical devices), identify the applicable EU directives, such as: Low Voltage Directive (LVD): Applies to electrical equipment with rated voltages between 50V and 1000V. Electromagnetic Compatibility Directive (EMC): Ensures devices do not interfere with other equipment and are immune to interference. Machinery Directive (MD): Covers all machinery products, including safety components. Standard References: Many directives have corresponding European harmonized standards (EN standards), such as EN 60335 (safety of household ...
- Source: drugdu
- 97
- October 1, 2025
Researchers design factor IX variants for short- and long-term Hemophilia B management

After blood vessel damage, effective blood clotting is essential to halt bleeding. However, this process is inefficient in some individuals due to hereditary factors. Hemophilia B, for example, results from a deficiency in coagulation factor IX (FIX), which can lead to prolonged bleeding after injuries or surgery. Thus, patients with hemophilia B are often treated with recombinant FIX as a replacement therapy, and while this approach has improved treatment for hemophilia B, the plasma half-lives of the approved products are only about 3-4 days, and frequent injections are needed. Consequently, there is a pressing need for recombinant FIX products with enhanced plasma half-life that allows less frequent dosing. In the current study, the laboratories of Professor Jan Terje Andersen at the University of Oslo and Alessio Branchini/Mirko Pinotti at the University of Ferrara (Italy) present design and characterization of long-acting human albumin-fused FIX variants, each exhibiting unique pharmacokinetic properties. The ...
- Source: drugdu
- 94
- September 30, 2025

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.